At the news
? NEUTRALIMPACT 4/10 6-K filed Nov 3, 2026 at 08:12 ET
Chemomab Therapeutics filed a Form 6-K to incorporate by reference into its registration statements the S-4 registration statement for its pending merger with Scipher Medicine Corporation, which was declared effective on October 30, 2026. The filing includes audited and unaudited financial statements of both companies and pro forma combined financial information. This is a procedural step advancing the merger, which was originally announced on July 7, 2026.
- Chemomab entered into a merger agreement on July 7, 2026 with Snowdrift Parent Corporation, Snowdrift Sub Corp., Elderwood Ltd. and Scipher Medicine Corporation.
- The S-4 registration statement was declared effective by the SEC on October 30, 2026.
- This 6-K incorporates by reference selected definitions, business descriptions, financial statements, and pro forma combined financial information from the S-4 into Chemomab's existing F-3 and S-8 registration statements.
- The consent of Deloitte & Touche LLP, Scipher's independent auditor, is filed as Exhibit 23.1.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access